Genomic Biomarkers : Rapid advancements in NGS and PCR technologies

 According to recent market analysis, the Genomic Biomarkers Market is projected to grow from USD 29.00 billion in 2025 to USD 50.31 billion by 2030, registering a robust CAGR of 11.6% during the forecast period. This growth reflects the increasing reliance on genomic insights to enhance clinical decision-making and therapeutic outcomes. The global genomic biomarkers market is witnessing strong momentum as precision medicine reshapes modern healthcare and drug development strategies.

Download PDF Brochure:- https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=48860286 

What is driving this surge, and why is it critical for industry leaders today? 

The expansion of the genomic biomarkers market is closely linked to the growing adoption of genomic testing across oncology, rare diseases, and inherited disorders. Why are organizations prioritizing these technologies? Advances in polymerase chain reaction (PCR) and next-generation sequencing (NGS) are enabling faster, more accurate, and cost-effective genomic analysis, making biomarker-driven diagnostics and therapies more accessible at scale.

Among technologies, next-generation sequencing (NGS) accounted for the largest market share in 2024. How is NGS transforming the landscape? Its ability to analyze hundreds of genes and complex molecular signatures in a single run makes it indispensable for comprehensive tumor profiling and the discovery of prognostic and predictive biomarkers. Hospitals, cancer centers, and pharmaceutical companies are increasingly leveraging NGS to enhance diagnostic precision and accelerate biomarker identification.

From an end-user perspective, pharmaceutical and biotechnology companies emerged as the fastest-growing segment in 2024. What is fueling this growth? These organizations integrate genomic biomarkers throughout the drug development lifecycle—from target discovery and patient stratification to response monitoring and companion diagnostic development. This end-to-end utilization generates consistent testing demand and strengthens the role of biomarkers in advancing personalized therapeutics.

Speak To Analyst:- https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=48860286

Regional Insights:

Where is the market gaining the most traction? North America led the global genomic biomarkers market in 2024, supported by a strong ecosystem of academic medical centers, cancer institutes, and commercial laboratories. The widespread adoption of NGS-based testing, liquid biopsies, and companion diagnostics has reinforced the region’s leadership. Additionally, favorable reimbursement frameworks, government initiatives such as the Cancer Moonshot, and significant investments in biomarker-driven clinical trials continue to drive regional growth.

Key Market Insights:

Key players shaping the competitive landscape include Thermo Fisher Scientific Inc. (US), F. Hoffmann-La Roche Ltd (Switzerland), Illumina, Inc. (US), QIAGEN (Germany/Netherlands), Bio-Rad Laboratories, Inc. (US), Agilent Technologies, Inc. (US), Eurofins Scientific (Luxembourg), and Quanterix (US). These companies are actively advancing innovation through product development, strategic collaborations, and expansion of genomic testing capabilities to meet growing global demand.

Global Catheters Market Set to Reach $45.99 Billion by 2030 Amid Rising Healthcare Demand

 According to MarketsandMarkets™, The report "Catheters Market By Type [Cardiovascular (Electrophysiology, Coronary Balloon, IVUS/OCT), Intravenous (CVC, PIVC, Midline), Urological, Neurovascular], Indication (Cardiac, Vascular, Kidney, Blood Transfusion, IV Medication Delivery and Fluid Management) – Global Forecast to 2030", is projected to reach USD 45.99 billion by 2030, growing from USD 30.53 billion in 2025 at a CAGR of 8.5% during the forecast period.

 
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=6247803
 
Browse

• 455     Market Data Tables
• 67       Figures
• 415     Pages and in-depth TOC on " Catheters Market - Global Forecast to 2030”.

Some of the prominent key players are:

• Boston Scientific Corporation (US),
• Medtronic PLC (Ireland),
• B. Braun SE (Germany),
• Becton Dickinson and Company (US),
• Stryker Corporation (US),
• Abbott Laboratories (US), and many more.....

Mergers & acquisitions, investments & expansions, partnerships & collaborations, and new product developments are some of the major strategies adopted by these key players to enhance their positions in the Catheters Market.

Speak To Analyst: https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=6247803

• The cardiovascular catheters segment accounted for the largest global catheters market in 2024. It is projected to grow at the highest rate during the forecast period. This growth is fueled by the increasing incidence of heart conditions, such as coronary artery disease, heart failure, and arrhythmias, particularly among older adults.
• The neurovascular conditions segment is projected to grow at the highest CAGR in the global catheters market from 2025 to 2030. This growth is mainly driven by the rising number of neurological disorders, such as stroke, brain aneurysms, and arteriovenous malformations, which often require catheter-based interventions.
• Asia Pacific is projected to witness the fastest growth in the global catheters market during the forecast period, mainly due to the rising prevalence of chronic diseases such as cardiovascular and kidney disorders, and a rapidly aging population. Increasing healthcare awareness, improving access to medical facilities, and expanding government investments in healthcare infrastructure also boost demand for catheter-based procedures.

The catheters market is projected to grow steadily, supported by the rising use of minimally invasive and image-guided procedures in the cardiovascular, urology, and neurology fields. Technological advancements—such as pressure-sensitive and steerable catheters, drug-coated devices, and infection-resistant coatings—enhance treatment effectiveness and lower risks. Integrating AI-based navigation systems and real-time imaging, particularly in interventional cardiology and neurology, improves accuracy in complex procedures. Furthermore, establishing hybrid catheter labs and advanced surgical suites in high-end healthcare facilities enables more sophisticated treatments. These innovations, combined with growing cases of chronic and lifestyle-related conditions, are driving continuous demand and shaping the market’s long-term growth outlook.

Interventional Oncology Market : Growing preference for targeted treatments

According to the latest market analysis, the Interventional Oncology Market is projected to grow from USD 2.75 billion in 2024 to USD 4.24 billion by 2029, registering a CAGR of 9.0% during the forecast period. The global interventional oncology market is witnessing steady expansion as healthcare systems increasingly prioritize minimally invasive, targeted cancer therapies.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=203687164

What is fueling this shift, and why is it critical for healthcare leaders today? 

The growth of interventional oncology is closely linked to the rising global incidence of cancer and the need for precise, less invasive treatment options. How are healthcare providers addressing complex and inoperable tumors? Interventional oncology techniques—such as embolization, thermal ablation, and targeted radiation therapies—offer localized treatment with reduced systemic side effects, improving patient outcomes while lowering hospital burden.

Among devices and consumables, embolization devices are expected to account for the largest market share during the forecast period. Why are these devices leading adoption? Their ability to deliver targeted therapy directly to tumors through minimally invasive procedures such as transarterial chemoembolization (TACE) and radioembolization has significantly improved clinical outcomes, particularly in liver cancer cases. Advances in embolic materials, including drug-eluting beads and radioactive microspheres, have enhanced precision and therapeutic efficacy, further accelerating their adoption.

By cancer type, liver cancer is projected to dominate the market. What makes this segment so critical? The increasing global incidence of hepatocellular carcinoma—driven by chronic hepatitis infections, alcohol consumption, and non-alcoholic fatty liver disease—has intensified demand for effective treatment solutions. Interventional oncology procedures such as TACE, transcatheter arterial radioembolization (TARE), and percutaneous ablation provide targeted tumor control, fewer side effects, and improved survival rates compared to conventional therapies.

From a procedural standpoint, TARE (also known as selective internal radiation therapy or SIRT) is expected to hold the largest share. How does TARE redefine cancer treatment? By delivering Yttrium-90-loaded microspheres directly into the tumor’s blood supply, this technique ensures localized radiation exposure while preserving healthy tissues. Its superior safety profile, better tolerance, and effectiveness in treating unresectable liver cancers and metastatic conditions make it a preferred choice among clinicians.

Hospitals are anticipated to remain the dominant end users in the interventional oncology market. Who is driving adoption at scale? Large hospitals and tertiary care centers, equipped with advanced imaging systems, catheterization labs, and multidisciplinary oncology teams, are at the forefront of implementing these complex procedures. Their ability to provide comprehensive care—from diagnosis to post-treatment follow-up—positions them as primary hubs for interventional oncology services.

Regional Analysis:

Regionally, North America continues to lead the market, supported by advanced healthcare infrastructure, high adoption of cutting-edge technologies, and a growing cancer patient population. Where is demand most concentrated? The United States, with its robust network of specialized cancer centers and skilled interventional radiologists, remains a key contributor to regional growth. Increasing cases of liver, lung, and kidney cancers further reinforce the demand for minimally invasive treatment options.

Speak To Analyst:  https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=203687164

Market Insights:

The interventional oncology market is highly competitive, with key players such as Siemens Healthineers AG (Varian), Medtronic, Boston Scientific Corporation, Terumo Corporation, Merit Medical Systems, Johnson & Johnson MedTech (Ethicon), Stryker, Teleflex Incorporated, AngioDynamics, Cook, Olympus Corporation, and Guerbet driving innovation. How are these companies shaping the market landscape? Through continuous investment in advanced devices, strategic collaborations, and product innovation, they are expanding the scope and effectiveness of interventional oncology treatments globally.

Why This Matters Now:

As healthcare systems shift toward value-based care and precision medicine, interventional oncology is emerging as a strategic pillar in cancer treatment. For C-suite executives and decision-makers, the market presents significant opportunities to invest in advanced technologies, expand oncology capabilities, and improve patient outcomes while optimizing operational efficiency.

Molecular Cytogenetics Market to Reach $1.43 Billion by 2030

 According to MarketsandMarkets™, the global Molecular Cytogenetics Market is projected to grow from USD 1.02 billion in 2025 to USD 1.43 billion by 2030, registering a CAGR of 7.1% during the forecast period. Market growth is primarily driven by the increasing incidence of cancer and genetic disorders, along with a growing emphasis on targeted therapies and personalized medicine.

The rising aging population and the subsequent increase in chronic disease prevalence are amplifying the demand for advanced genetic testing solutions. Additionally, the expanding role of molecular cytogenetics in clinical pathology is accelerating its adoption across healthcare systems, positioning these technologies as critical tools in precision diagnostics.

Download PDF Brochure:- https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=148469224 

Key Market Insights

By product & service, the kits & reagents segment is expected to register the highest growth during the forecast period. Their widespread adoption in research, diagnostics, and clinical applications is driven by the need for standardized, accurate, and reproducible testing solutions. Ready-to-use kits and specialized reagents streamline laboratory workflows by reducing the need for complex preparation processes, while ongoing innovations in probes and assay technologies continue to expand their application scope.

Technology Trends

By technique, the comparative genomic hybridization (CGH) segment accounted for the largest share of the molecular cytogenetics market and is expected to maintain its dominance. CGH enables the detection of chromosomal abnormalities associated with developmental disorders, congenital anomalies, and cancer. Its ability to analyze copy number variations without the need for cell culturing significantly enhances efficiency and reliability. Advancements in array-based CGH further allow simultaneous, high-resolution analysis of multiple genomic regions, making it a powerful tool in oncology and genetic research.

Regional Outlook

The Asia Pacific region is projected to witness the fastest growth during the forecast period. This growth is supported by rising healthcare investments, increasing awareness of genetic testing, and expanding government initiatives to strengthen healthcare infrastructure. The region is also seeing increased participation from both domestic and global market players through partnerships and expansion strategies.

Speak To Analyst:-https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=148469224 

Competitive Landscape

The molecular cytogenetics market is competitive and innovation-driven, with leading companies focusing on product development, strategic collaborations, and geographic expansion. Key players in this market include Thermo Fisher Scientific Inc., Illumina, Inc., Danaher, F. Hoffmann-La Roche Ltd., Revvity, Abbott, Agilent Technologies, Inc., PacBio, Bio-Rad Laboratories, Inc., and Bio-Techne, among others.

As demand for advanced genetic analysis and precision medicine continues to rise, the molecular cytogenetics market is expected to experience steady growth, supported by technological advancements and expanding clinical applications.

Companion Animal Diagnostics Market to Reach $5.40 Billion by 2031

 According to MarketsandMarkets™, the global Companion Animal Diagnostics Market is projected to grow from USD 3.56 billion in 2026 to USD 5.40 billion by 2031, registering a CAGR of 8.7% during the forecast period. This growth is driven by rising pet ownership, increasing veterinary healthcare expenditure, and rapid advancements in diagnostic technologies.

The growing demand for fast, accurate, and cost-effective diagnostic solutions is transforming veterinary practices and laboratories. The adoption of advanced tools such as AI-powered image analysis, automated analyzers, in-clinic molecular diagnostics, and cloud-connected platforms is enhancing clinical workflows and enabling earlier and more precise disease detection in companion animals.

Download PDF Brochure:- https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=173823870 

Key Market Drivers

The increasing focus on preventive care, chronic disease monitoring, and personalized veterinary treatment is significantly boosting demand for advanced diagnostic solutions. Technological innovations, including liquid biopsy, improved assay chemistry, and integrated data systems, are enhancing diagnostic accuracy, traceability, and regulatory compliance. Additionally, growing collaboration among diagnostic companies, veterinary laboratories, and technology providers is fostering the development of scalable, data-driven diagnostic ecosystems.

Segment Insights

By application, the clinical pathology segment accounted for the largest market share in 2025. This segment forms the backbone of routine veterinary diagnostics, encompassing hematology, biochemistry, urinalysis, cytology, and electrolyte analysis. Its widespread adoption is driven by high testing volumes, rapid turnaround times, and its critical role in diagnosing infections, metabolic disorders, and chronic diseases in pets.

By end user, the homecare settings segment is expected to register the highest CAGR during the forecast period. The increasing adoption of at-home diagnostic solutions, coupled with rising demand for convenient and continuous pet health monitoring, is driving this segment’s growth. Advancements in digital health tools and remote diagnostics are further supporting this trend.

Regional Outlook

North America accounted for the largest share of the companion animal diagnostics market in 2025. The region’s dominance is attributed to high pet ownership rates, advanced veterinary healthcare infrastructure, and strong adoption of innovative diagnostic technologies. Additionally, increasing awareness of preventive care, availability of pet insurance, and the presence of leading market players are further supporting market growth in this region.

Speak To Analyst:- https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=173823870 

Competitive Landscape

The companion animal diagnostics market is highly competitive, with leading players focusing on innovation, partnerships, and expansion strategies. Key companies operating in this space include IDEXX Laboratories, Zoetis Services LLC, Mars, Incorporated, bioMérieux, FUJIFILM Corporation, Thermo Fisher Scientific Inc., Neogen Corporation, Virbac, INDICAL BIOSCIENCE GmbH, and Innovative Diagnostics, among others.

As veterinary healthcare continues to evolve toward precision diagnostics and digital integration, the companion animal diagnostics market is expected to witness sustained growth, driven by innovation, increasing pet care awareness, and expanding global demand.

Medical Device Engineering Market to Reach $14.7 Billion by 2029

 According to MarketsandMarkets™,  the global Medical Device Engineering Market is projected to grow from USD 9.0 billion in 2024 to USD 14.7 billion by 2029, registering a strong CAGR of 10.1% during the forecast period. This growth is driven by rapid advancements in healthcare infrastructure, rising healthcare expenditure, and increasing demand for innovative, cost-effective medical technologies worldwide.

The emerging economies such as China, India, and Brazil are playing a pivotal role in shaping market expansion. Significant investments in healthcare modernization, improved access to medical services, and the adoption of advanced technologies are creating substantial opportunities for engineering service providers. These players are increasingly offering end-to-end solutions, including product design, development, and regulatory compliance, to meet evolving regional needs.

Download PDF Brochure:- https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=266679113 

Key Market Drivers

The rising demand for technologically advanced medical devices, coupled with the growing complexity of regulatory requirements, is accelerating the need for specialized engineering services. Additionally, the increasing integration of artificial intelligence (AI), connectivity, and mobility solutions in medical devices is transforming the landscape, enabling enhanced patient outcomes and operational efficiency.

Segment Insights

By service type, the software development & testing services segment is expected to witness the fastest growth during the forecast period. The surge in AI-enabled medical devices and digital health solutions is driving demand for robust software platforms and rigorous validation processes to ensure clinical accuracy, safety, and compliance with regulatory standards.

By device type, the diagnostic imaging equipment segment is projected to experience the most rapid expansion. The growing adoption of minimally invasive procedures, supported by high-resolution and 3D imaging technologies, is significantly boosting demand for advanced imaging systems. Integration of AI and machine learning further enhances diagnostic precision and procedural outcomes.

Regional Outlook

The Asia Pacific region is anticipated to record the highest growth rate during the forecast period. The region’s emergence as a global hub for medical tourism, combined with cost-effective healthcare services and advanced medical facilities, is attracting a large international patient base. This influx is increasing demand for cutting-edge medical devices, thereby driving the need for sophisticated engineering services to support innovation and deployment.

Speak To Analyst:- https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=266679113

Competitive Landscape

The medical device engineering market is highly competitive, with companies focusing on strategic initiatives such as partnerships, acquisitions, product launches, and geographic expansion. Key players include L&T Technology Services Limited, Infosys Limited, HCL Technologies Limited, Cyient, Wipro, Tech Mahindra Limited, Tata Consultancy Services Limited, Flex Ltd., Capgemini, Alten Group, Accenture, and Veranex, among others.

As healthcare systems worldwide continue to evolve toward digitalization and precision medicine, the demand for specialized engineering expertise is expected to rise, positioning the medical device engineering market for sustained growth in the coming years.

Chromatography Accessories & Consumables Market to Reach $8.74 Billion by 2030

 According to the latest report, “Chromatography Accessories & Consumables Market by Technology (GC, HPLC, UPLC, LPLC, Flash), Product (Columns, Detectors, Autosamplers, Vials, Septa, Degassers), End User (Pharma-Biopharma, Academia, F&B, O&G) – Global Forecasts to 2030,” the market is projected to grow from USD 6.10 billion in 2025 to USD 8.74 billion by 2030, at a CAGR of 7.5%.

Download PDF Brochure:- https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=1294 

What is driving the sustained growth of this market, and why is it increasingly relevant for industry leaders?

The expansion is fueled by rising R&D investments across pharmaceutical and biopharmaceutical sectors, along with the growing adoption of hyphenated chromatography techniques that enhance analytical precision. Additionally, the increasing application of chromatography in food safety testing and environmental analysis is elevating its role as a critical tool for regulatory compliance and public health assurance.

How are evolving industry requirements shaping demand? The need for high-throughput, accurate, and scalable analytical solutions is driving the adoption of advanced chromatography systems and consumables. Chromatography plays a pivotal role in drug discovery and development processes, enabling efficient separation, identification, and quantification of compounds—making it indispensable for innovation-driven industries.

Where are the emerging opportunities? Untapped markets in developing regions, coupled with increased outsourcing of research activities, are creating new growth avenues. At the same time, competitive dynamics among key players are encouraging innovation and strengthening brand differentiation strategies.

Segment Insights:

Why is liquid chromatography leading the technology segment? Liquid chromatography is expected to dominate the market throughout the forecast period due to its versatility, flexibility, and broad application range. Techniques such as high-performance liquid chromatography (HPLC), ultra-performance liquid chromatography (UPLC), flash chromatography, and low-pressure liquid chromatography (LPLC) are widely used for high-throughput purification and analysis, supporting large-scale laboratory operations and industrial workflows.

What makes columns the largest product segment? In 2024, the columns segment accounted for the largest share of the market, as chromatographic separation occurs within the column itself, making it a critical component of any system. Increasing concerns related to food and water safety are further driving demand for high-performance columns, reinforcing their central role in analytical processes.

Regional Insights:

Where is the fastest growth expected globally? The Asia Pacific region is projected to register the highest CAGR during the forecast period. What factors are contributing to this growth? Rising outsourcing of drug discovery and development activities to cost-efficient markets, coupled with the rapid expansion of the biopharmaceutical industry, is driving regional demand. Countries such as China, India, South Korea, Taiwan, and Singapore are emerging as key hubs for analytical and research activities.

Speak To Analyst :- https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=1294 

Who are the key players shaping the competitive landscape?

Leading companies in the chromatography accessories & consumables market include Agilent Technologies, Inc., Bio-Rad Laboratories, Inc., Waters Corporation, Thermo Fisher Scientific Inc., Jasco International Co. Ltd., PerkinElmer Inc., Bruker, Restek Corporation, Shimadzu Corporation, Avantor, Inc., and Merck KGaA. These organizations are focusing on product innovation, portfolio expansion, and strategic collaborations to strengthen their global presence.

How will the market evolve in the coming years? As industries increasingly prioritize quality, compliance, and efficiency, demand for advanced chromatography consumables and accessories is expected to rise. Companies that invest in high-performance technologies and expand into emerging markets will be better positioned to capture long-term growth opportunities.

Understanding the Hemodialysis Procedure

Hemodialysis is a life-saving medical procedure used to treat patients with kidney failure. When the kidneys can no longer function properly, they are unable to filter toxins and excess fluids from the blood. Hemodialysis steps in to perform this vital function, helping maintain balance in the body and prolong life.

How It Works

The process of hemodialysis involves diverting the patient's blood through a machine called a dialyzer, often referred to as an "artificial kidney." This machine cleans the blood by removing waste products and excess fluids, then returns the filtered blood back into the patient's body.

Blood is drawn from the patient through a vascular access point, typically created surgically in the arm. The blood flows through the dialyzer, where it is filtered by a semipermeable membrane. A special dialysate solution on the other side of the membrane helps draw out unwanted substances, allowing the clean blood to be returned.

Frequency and Duration

Hemodialysis is usually performed several times a week, with each session lasting around four hours. The frequency and duration may vary depending on the patient's medical condition and the type of dialysis treatment they are receiving.

Impact on Lifestyle

While hemodialysis significantly improves the quality of life for patients with kidney failure, it requires a substantial commitment in terms of time and lifestyle adjustments. Patients often need to adhere to a strict diet and fluid intake restrictions to manage their condition between treatments.

Advancements in Hemodialysis

Recent advancements in technology have improved the efficiency and comfort of hemodialysis, with options like home dialysis offering greater flexibility for patients. Despite these improvements, hemodialysis remains a critical procedure for many individuals with end-stage renal disease, helping them live longer and healthier lives.

Image-Guided Radiation Therapy Market Valuation to Climb to $2.4 Billion by 2028

 The Image-Guided Radiation Therapy Market Forecast shows significant growth due to advancements in healthcare infrastructure, increasing cancer prevalence, and favorable reimbursement policies. Key technological innovations, regulatory frameworks, and the rising adoption of minimally invasive procedures further support market expansion, although competition from alternative treatments like IMRT could constrain growth.

The report Image-Guided Radiation Therapy Market is projected to reach USD 2.4 billion by 2028 from USD 1.9 billion in 2023, growing at a CAGR of 5.2% during the forecast period.

Download PDF Brochure: - https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=171554723

Market Segmentation: -

PET/ MRI-guided radiation therapy segment to register a significant growth rate over the forecast period of 2022-2028.

Based on the product, the image-guided radiation therapy market is segmented into LINAC (linear accelerator), 4D gating/ 4D RT, PET/ MRI-guided radiation therapy, CT scanning, and portal imaging. The capability of PET/MRI to furnish functional insights directs the administration of radiation doses, effectively mitigating healthy tissue exposure and subsequently alleviating the occurrence of adverse effects. This contribution significantly bolsters the market trajectory of image-guided radiation therapy, enhancing its appeal and positioning within the healthcare landscape.

The breast cancer application segment accounted for a significant share of the image-guided radiation therapy market in 2022-2028.

Based on the application, the image-guided radiation therapy market is segmented into breast cancer, prostate cancer, head & neck cancer, lung cancer, gastrointestinal cancer, gynecological cancer, and other applications. The rising incidence of cancer worldwide is a significant driver for the image-guided radiation therapy market. The precision inherent in image-guided radiation therapy (IGRT) mitigates the necessity for frequent and discomforting repositioning of patients during treatment sessions.

 

Intensity modulation radiation therapy procedure segment accounted for the largest share of the image-guided radiation therapy market in 2022-2028.

Based on the procedure, the image-guided radiation therapy market is segmented into 3D conformal therapy, stereotactic therapy, proton beam therapy, intensity modulation radiation therapy,  and particle therapy. The intensity modulation radiation therapy procedure segment is estimated to hold the 39.2%  market share of the image-guided radiation therapy market in 2022. Intensity Modulated Radiation Therapy (IMRT) is instrumental in crafting tailored treatment blueprints through the optimization of radiation administration based on tumor dimensions, contours, and placement. This congruence aligns seamlessly with the personalized treatment ethos central to Image-Guided Radiation Therapy (IGRT).

Hospitals segment to register for the largest market share of the image-guided radiation therapy market in 2022-2028.

The major end users in the image-guided radiation therapy market are independent radiotherapy centers and hospitals. Hospitals are expected to account for a major market share in 2022. Healthcare institutions grapple with a considerable influx of cancer patients, thereby magnifying the attraction towards image-guided radiation therapy (IGRT). The precision inherent in IGRT's tumor-targeting proficiency and its streamlined treatment delivery harmonize seamlessly with the necessity of proficiently managing the patient caseload.

Regional Analysis:-

In 2022, the North American region is expected to register significant growth in the market during the forecast period. North America comprises the US and Canada. North America has an advanced healthcare infrastructure, which is associated with a higher incidence of cancer. In North America, a highly developed healthcare infrastructure coupled with ready access to state-of-the-art medical technologies creates a conducive environment for the assimilation of progressive treatment modalities, such as image-guided radiation therapy (IGRT).

Key Players:-

As of 2022, prominent players in the image-guided radiation therapy market are Siemens Healthineers AG (Germany), Elekta (Sweden), and Accuray Incorporated (US), among others.

Recent developments

Recent developments, such as Philips' Zenition 10, GE HealthCare's advances in PET/MR capabilities, and the launch of Pixxoscan, highlight the industry's commitment to advancing cancer care.

Conclusion

Image-Guided Radiation Therapy is revolutionizing cancer treatment by offering precise, patient-centric care. As a medical industry expert, I'm thrilled to witness this transformation. With continued advancements, a supportive healthcare ecosystem, and a global focus on non-invasive cancer interventions, IGRT is set to play a pivotal role in shaping the future of cancer treatment worldwide. As the industry embraces innovation, research, and collaboration, the promise of improved cancer outcomes becomes increasingly achievable.

Content Source: -

Image-Guided Radiation Therapy Market Report

Image-Guided Radiation Therapy Market Press Release

An Overview of Long-Read Sequencing Technology

Long-read sequencing, also known as third-generation sequencing, is a cutting-edge technology in genomics that offers significant advantages over traditional short-read sequencing. Long-Read Sequencing Technology is characterized by its ability to generate much longer DNA or RNA sequences, providing a more comprehensive view of the genome.

Key Technologies

Two major platforms dominate the long-read sequencing market:

1. Pacific Biosciences (PacBio): PacBio’s Single-Molecule Real-Time (SMRT) sequencing technology reads long stretches of DNA by tracking the incorporation of nucleotides in real-time. This method produces high-accuracy long reads, known as HiFi reads, which can reach up to 20,000 base pairs in length, enabling detailed genome assemblies and variant detection.

2. Oxford Nanopore Technologies: Oxford Nanopore’s sequencing technology passes DNA or RNA molecules through nanopores, generating ultra-long reads in real-time. This platform allows sequencing of entire chromosomes in one read, making it highly flexible and capable of reading even extremely long DNA sequences of up to millions of base pairs.

Advantages of Long-Read Sequencing Technology

• Longer Read Lengths: Long-read sequencing can generate reads ranging from several kilobases to even megabases, providing better resolution for complex regions of the genome, including structural variants and repetitive sequences.

• Real-Time Data: Both PacBio and Oxford Nanopore provide real-time sequencing data, enabling rapid insights into genomic data without waiting for the entire sequencing run to complete.

• De Novo Genome Assembly: Long-read sequencing is ideal for assembling genomes from scratch, providing a more complete and accurate assembly by bridging gaps left by short-read technologies.

• Epigenetic Information: Nanopore sequencing can also detect epigenetic modifications, such as DNA methylation, without additional chemical treatments, offering insights into gene regulation mechanisms.

Applications

Long-read sequencing technology has transformative applications in various fields, including:

• Human Genomics: It improves the detection of structural variants and complex genetic regions, aiding in the study of diseases and personalized medicine.
• Agrigenomics: In plant and animal genomics, long-read sequencing helps in the accurate assembly of complex genomes, leading to advances in agriculture and conservation.
• Microbial Genomics: Long-read sequencing is crucial in microbial studies for resolving complete genomes and studying antibiotic resistance genes.

In conclusion, long-read sequencing technology represents a significant leap forward in genomics, offering more accurate, detailed, and comprehensive genetic information. It is poised to revolutionize research in many areas, from human health to biodiversity.